Phase II Single Agent Study of Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2018
Price : $35 *
At a glance
- Drugs Selinexor (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 29 May 2018 Status changed from active, no longer recruiting to discontinued.
- 02 Mar 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2019.